<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00285103</url>
  </required_header>
  <id_info>
    <org_study_id>SPC2996-101</org_study_id>
    <nct_id>NCT00285103</nct_id>
  </id_info>
  <brief_title>SPC2996 in Chronic Lymphocytic Leukaemia</brief_title>
  <official_title>An Open-labelled, International, Multicenter, Dose Escalating, Phase I/II Study of SPC2996,an LNA Antisense Molecule Against Bcl-2, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santaris Pharma A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santaris Pharma A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether SPC2996 is effective and safe in the
      treatment of Chronic Lymphocytic Leukaemia (CLL)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic Lymphocytic Leukaemia (CLL) is the most common leukaemia in adults in the US and most
      of Western Europe. Many patients suffering from CLL have tumour cells expressing high amounts
      of Bcl-2 protein. Since over expression of Bcl-2 inhibits apoptosis, it is possible that this
      gene participates in the pathogenesis of CLL. By lowering the Bcl-2 protein in these tumour
      cells the cells may go into apoptosis due to changed balance in pro- and anti apoptotic
      proteins and thereby it might be possible to induce a tumour response.

      The study is an open-labelled, international, multicenter, dose escalating phase I/II study
      where patients receive 6, 3, 2 or 1 dose(s) of SPC2996, a LNA antisense molecule against
      Bcl-2, over a period of up to 2 weeks, and are followed for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Bcl-2 m-RNA levels</measure>
    <time_frame>from Day 0 to Day 13</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Bcl-2 protein expression. Change in Bcl-2 m-RNA levels (and other parameters)</measure>
    <time_frame>from Day 0 to Day 14 and during study respectively</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPC2996</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with relapsed or refractory Chronic Lymphocytic Leukaemia requiring therapy

          -  screening blood sample must show circulating lymphocyte count of more then 5 x 109/L
             and circulating lymphocytes expressing the phenotype CD5+CD20+CD23+.

          -  The PCR Bcl-2 m-RNA level must be positive

          -  the patients must be 18 years or older and have given informed consent.

        Exclusion Criteria:

          -  previous treatment with rituximab, alemtuzumab or autologous stem cell transplantation
             within 6 months prior to Visit 1 or allogeneic stem cell transplantation at any time

          -  patients that received anti-cancer therapy, glucocorticoids or radiotherapy within 4
             weeks prior to Visit 1 and patients with known or suspected transformation of CLL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Betrand Coiffier, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Lyon Sud, Lyon, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center, Univ. of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KAS Herlev</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Sygehus</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'HÃ©matologieCentre Hospitalier Lyon-Syd</name>
      <address>
        <city>Lyon</city>
        <state>Cedex</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bruno Cazin</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mauricette Michellet</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MRC Toxicology Unit, University of Leicester</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 9HN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Surrey</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>January 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2006</study_first_posted>
  <last_update_submitted>February 1, 2011</last_update_submitted>
  <last_update_submitted_qc>February 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2011</last_update_posted>
  <keyword>Antisense, mRNA antagonist, Bcl-2, CLL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

